z-logo
Premium
A DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, FIXED‐DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
Author(s) -
Gommoll Carl,
Durgam Suresh,
Mathews Maju,
Forero Giovanna,
Nunez Rene,
Tang Xiongwen,
Thase Michael E.
Publication year - 2015
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/da.22365
Subject(s) - placebo , nausea , partial agonist , medicine , repeated measures design , generalized anxiety disorder , major depressive disorder , adverse effect , anxiety , psychology , anesthesia , psychiatry , agonist , receptor , statistics , alternative medicine , mathematics , pathology , amygdala
Background Vilazodone, a selective serotonin reuptake inhibitor and 5‐HT 1A receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov ) evaluated the efficacy and safety of vilazodone in adults with generalized anxiety disorder (GAD). Methods A multicenter, double‐blind, parallel‐group, placebo‐controlled, fixed‐dose study in patients with GAD randomized (1:1:1) to placebo ( n = 223), or vilazodone 20 mg/day ( n = 230) or 40 mg/day ( n = 227). Primary and secondary efficacy parameters were total score change from baseline to week 8 on the Hamilton Rating Scale for Anxiety (HAMA) and Sheehan Disability Scale (SDS), respectively, analyzed using a predefined mixed‐effect model for repeated measures (MMRM). Safety outcomes were presented by descriptive statistics. Results The least squares mean difference (95% confidence interval) in HAMA total score change from baseline (MMRM) was statistically significant for vilazodone 40 mg/day versus placebo (–1.80 [–3.26, –0.34]; P = .0312 [adjusted for multiple comparisons]), but not for vilazodone 20 mg/day versus placebo. Mean change from baseline in SDS total score was not significantly different for either dose of vilazodone versus placebo when adjusted for multiplicity; significant improvement versus placebo was noted for vilazodone 40 mg/day without adjustment for multiplicity ( P = .0349). The incidence of adverse events was similar for vilazodone 20 and 40 mg/day (∼71%) and slightly lower for placebo (62%). Nausea, diarrhea, dizziness, vomiting, and fatigue were reported in ≥5% of patients in either vilazodone group and at least twice the rate of placebo. Conclusions Vilazodone was effective in treating anxiety symptoms of GAD. No new safety concerns were identified.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here